文献速递神经肿瘤功能神经外科

可见5-ALA荧光与定量PpIX分析在疑似低级别胶质瘤手术中的价值

The value of visible 5-ALA fluorescence and quantitative protoporphyrin IX analysis for improved surgery of suspected low-grade gliomas.
PubMed 文献 · J Neurosurg · 2019-05-10

该前瞻性研究纳入22例疑似弥漫性浸润性低级别胶质瘤(LGG)患者,术中评估可见5-ALA荧光与光谱探针定量原卟啉IX(PpIX)浓度。结果显示可见荧光仅见于多数高级别胶质瘤(HGG)而无一例LGG,但定量PpIX分析可在无可见荧光的LGG组织中检出显著升高的PpIX,有助于提高切除与取材精度。

要点

  • 可见5-ALA荧光在多数HGG局灶区出现,但8例LGG均无可见荧光。
  • 定量PpIX在荧光样本中显著高于无荧光样本(0.693 vs 0.008 μg/ml,p<0.001)。
  • 无可见荧光的35份样本中14份(40%)及32份LGG样本中16份(50%)PpIX显著升高(cutoff 0.005 μg/ml)。

核心结论

  • 可见5-ALA荧光可检测肿瘤内恶性转化的局灶区域,定量PpIX分析尤其有助于发现常规荧光无法识别的LGG组织。
  • 两种技术可辅助神经外科医生在疑似LGG手术中实现最大安全切除并提高取材精度。

研究设计与样本

  • 前瞻性招募放射学疑似弥漫性浸润性LGG患者,术前给予5-ALA。
  • 术中采用光谱手持探针测量不同瘤内区域的绝对组织PpIX浓度(CPpIX)并记录可见荧光。
  • 共收集22例组织病理确诊弥漫性浸润性胶质瘤患者的69份样本,按WHO 2016标准诊断并分析肿瘤分级与肿瘤细胞百分比。

主要发现

  • 可见荧光见于多数HGG的局灶区域(79%),但8例LGG均无可见荧光。
  • 荧光样本平均CPpIX显著高于无荧光样本(0.693 μg/ml vs 0.008 μg/ml,p<0.001)。
  • 荧光样本平均肿瘤细胞百分比显著高于无荧光样本(62% vs 34%,p=0.005),CPpIX与肿瘤细胞百分比显著相关(r=0.362,p=0.002)。
  • 荧光样本中高级别组织学显著更常见(p=0.001),但HGG与LGG样本间平均CPpIX无统计学显著差异。
  • 最大CPpIX与总体肿瘤分级相关性高度显著(p=0.005)。

关键数值与推荐

  • 无可见荧光的35份肿瘤样本中14份(40%)及32份LGG样本中16份(50%)显示CPpIX显著升高,cutoff值为0.005 μg/ml。

临床怎么用

  • 对疑似LGG,除肉眼观察5-ALA荧光外,可结合光谱探针定量PpIX以发现无可见荧光但PpIX升高的肿瘤组织。
  • 定量PpIX升高区域可能提示肿瘤细胞密度较高或存在恶性转化,有助于指导取材与切除范围。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In patients with suspected diffusely infiltrating low-grade gliomas (LGG), the prognosis is dependent especially on extent of resection and precision of tissue sampling. Unfortunately, visible 5-aminolevulinic acid (5-ALA) fluorescence is usually only present in high-grade gliomas (HGGs), and most LGGs cannot be visualized. Recently, spectroscopic probes were introduced allowing in vivo quantitative analysis of intratumoral 5-ALA-induced protoporphyrin IX (PpIX) accumulation. The aim of this study was to intraoperatively investigate the value of visible 5-ALA fluorescence and quantitative PpIX analysis in suspected diffusely infiltrating LGG. METHODS: Patients with radiologically suspected diffusely infiltrating LGG were prospectively recruited, and 5-ALA was preoperatively administered. During resection, visual fluorescence and absolute tissue PpIX concentration (CPpIX) measured by a spectroscopic handheld probe were determined in different intratumoral areas. Subsequently, corresponding tissue samples were safely collected for histopathological analysis. Tumor diagnosis was established according to the World Health Organization 2016 criteria. Additionally, the tumor grade and percentage of tumor cells were investigated in each sample. RESULTS: All together, 69 samples were collected from 22 patients with histopathologically confirmed diffusely infiltrating glioma. Visible fluorescence was detected in focal areas in most HGGs (79%), but in none of the 8 LGGs. The mean CPpIX was significantly higher in fluorescing samples than in nonfluorescing samples (0.693 μg/ml and 0.008 μg/ml, respectively; p < 0.001). A significantly higher mean percentage of tumor cells was found in samples with visible fluorescence compared to samples with no fluorescence (62% and 34%, respectively; p = 0.005), and significant correlation of CPpIX and percentage of tumor cells was found (r = 0.362, p = 0.002). Moreover, high-grade histology was significantly more common in fluorescing samples than in nonfluorescing samples (p = 0.001), whereas no statistically significant difference in mean CPpIX was noted between HGG and LGG samples. Correlation between maximum CPpIX and overall tumor grade was highly significant (p = 0.005). Finally, 14 (40%) of 35 tumor samples with no visible fluorescence and 16 (50%) of 32 LGG samples showed significantly increased CPpIX (cutoff value: 0.005 μg/ml). CONCLUSIONS: Visible 5-ALA fluorescence is able to detect focal intratumoral areas of malignant transformation, and additional quantitative PpIX analysis is especially useful to visualize mainly LGG tissue that usually remains undetected by conventional fluorescence. Thus, both techniques will support the neurosurgeon in achieving maximal safe resection and increased precision of tissue sampling during surgery for suspected LGG.Clinical trial registration no.: NCT01116661 (clinicaltrials.gov).

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Widhalm G, Olson J, Weller J, et al. The value of visible 5-ALA fluorescence and quantitative protoporphyrin IX analysis for improved surgery of suspected low-grade gliomas. J Neurosurg. 2019. PMID: 31075771. doi:10.3171/2019.1.JNS182614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。